Medication info
Dimapholmin Extended-release Tablet (Metformin Hydrochloride)

Dimapholmin Extended-release Tablet (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Albozen Korea Co., Ltd.
Appearance
White, bilaterally convex, rectangular extended-release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200608278 · Approved 2006.08.23 · Insurance code 652604080

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Measure blood glucose after one week and adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with up to 2000mg once daily, consider administration of 1000mg twice daily; both doses should be taken with meals. - In patients already treated with metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At initiation of treatment and during dose adjustment, measure fasting blood glucose to assess the response to this drug and determine the minimum effective dose. Measure blood glycated hemoglobin approximately every 3 months. - The goal of treatment with this drug, whether given as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this drug should be discontinued immediately.

Ingredients

Manufacturer
Albozen Korea Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used for blood sugar management in adult patients with type 2 diabetes when dietary and exercise alone are insufficient, especially for overweight diabetic patients. It can be used alone or in combination with other oral hypoglycemic agents or insulin to aid in blood sugar control. It can be flexibly utilized according to the patient's condition to effectively improve blood glucose levels.

How to take

Adult dose

The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Measure blood glucose after one week and adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with up to 2000mg once daily, consider administration of 1000mg twice daily; both doses should be taken with meals. - In patients already treated with metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At initiation of treatment and during dose adjustment, measure fasting blood glucose to assess the response to this drug and determine the minimum effective dose. Measure blood glycated hemoglobin approximately every 3 months. - The goal of treatment with this drug, whether given as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this drug should be discontinued immediately.

Precautions

This medication can rarely cause a serious condition called lactic acidosis, so caution is required. Lactic acidosis occurs when lactate accumulates excessively in the body, and if symptoms appear, patients should immediately inform medical personnel. There is a risk of hypoglycemia when used in combination with other diabetes medications, so blood glucose status should be closely monitored. Patients with moderate to severe renal impairment or acute illnesses affecting the kidneys, such as dehydration or severe infections, should not use this medication. It should also be avoided in serious conditions like acute heart failure, myocardial infarction, and sepsis, and the medication must be discontinued before procedures using radiographic contrast agents. Patients with a history of allergic reactions to this medication or its ingredients, patients with type 1 diabetes, and those with metabolic acidosis should also not use it. Patients with severe infections, significant trauma, or before and after surgery should temporarily stop the medication, and resume only when their condition stabilizes. Caution is required for patients with poor nutritional status or liver dysfunction, and excessive alcohol intake should be avoided. During treatment, irregular meals, excessive exercise, and the use of interacting medications can increase the risk of lactic acidosis and hypoglycemia. Side effects may include vitamin B12 deficiency, gastrointestinal disturbances (such as nausea, vomiting, diarrhea), skin rashes, and while gastrointestinal symptoms commonly occur initially, they generally lessen over time. Renal function should be regularly tested, and if abnormalities are found, immediate consultation with a physician is necessary. Alcohol consumption can affect lactate metabolism, so it is advisable to avoid it during treatment. Pregnant women should consult medical personnel due to potential effects on the fetus, and nursing mothers should also consider careful judgment. Safety has not been established for pediatric patients, and elderly patients should be administered appropriate doses considering their kidney function. In the event of an overdose, dialysis may be necessary, and patients should visit a medical facility immediately. This medication should not be chewed or crushed, but swallowed whole, and it is normal for the tablet's coating to appear in the stool. Regular testing of blood sugar, kidney function, and vitamin B12 levels should be performed during treatment, and any unusual symptoms should be reported to healthcare personnel immediately.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. This will help preserve the medication's effectiveness over time.

Appearance and packaging

Appearance

White, bilaterally convex, rectangular extended-release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.